Article info

PDF

Extended report
Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate)

Authors

  1. Correspondence to Dr Dinesh Khanna, Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, Ann Arbor MI 48109, USA; khannad{at}med.umich.edu
View Full Text

Citation

Khanna D, Denton CP, Lin CJF, et al
Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate)

Publication history

  • Received April 21, 2017
  • Revised September 15, 2017
  • Accepted September 19, 2017
  • First published October 24, 2017.

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.